Potent and selective A2A adenosine receptor competitive antagonist (Ki = 1.3 nM). Displays 323-, 53- and 100-fold selectivity over A1, A2B and A3 receptors, respectively.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 345.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.9 mL||14.48 mL||28.96 mL|
|5 mM||0.58 mL||2.9 mL||5.79 mL|
|10 mM||0.29 mL||1.45 mL||2.9 mL|
|50 mM||0.06 mL||0.29 mL||0.58 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Zocchi et al (1996) Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. J.Pharmacol.Exp.Ther. 276 398 PMID: 8632302
Bastia et al (2002) Effects of A1 and A2A adenosine receptor ligands in mouse acute models of pain. Neurosci.Lett. 328 241 PMID: 12147316
If you know of a relevant reference for SCH 58261, please let us know.
View Related Products by Product Action
Keywords: Potent selective A2A antagonists Receptors adenosines SCH58261 Adenosine A2A Receptors
24 Citations for SCH 58261
Citations are publications that use Tocris products. Selected citations for SCH 58261 include:
Nadal et al (2016) Presynaptic muscarinic acetylcholine autoreceptors (M1, M2 and M4 subtypes), adenosine receptors (A1 and A2A) and tropomyosin-related kinase B receptor (TrkB) modulate the developmental synapse elimination process at the neuromuscular junction. Cancer Biol Ther 9 67 PMID: 27339059
Perez-Aso et al (2015) Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther 17 249 PMID: 26370839
Stoddart et al (2015) Application of BRET to monitor ligand binding to GPCRs. Nat Methods 12 661 PMID: 26030448
Kermanian et al (2015) Effects of adenosine A2a receptor agonist and antagonist on cerebellar nuclear factor-kB expression preceded by MDMA toxicity. J Neuroinflammation 28 120 PMID: 25678999
Madeira et al (2015) Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure. J Neurosci 12 115 PMID: 26054642
Zhu et al (2015) Different patterns of electrical activity lead to long-term potentiation by activating different intracellular pathways. Psychopharmacology (Berl) 35 621 PMID: 25589756
Wydra et al (2015) On the role of A2A and D2 receptors in control of cocaine and food-seeking behaviors in rats. Mol Brain 232 1767 PMID: 25420611
Häusler et al (2014) Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Neuroscience 6 129 PMID: 24489992
Haanes and Edvinsson (2014) Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine. Med J Islam Repub Iran 9 e108782 PMID: 25265286
Wu et al (2013) Opiate-induced changes in brain adenosine levels and narcotic drug responses. J Neuroinflammation 228 235 PMID: 23098802
Augusto et al (2013) Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. Proc Natl Acad Sci U S A 33 11390 PMID: 23843511
Hikida et al (2013) Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via selective transmitter receptors. Nat Neurosci 110 342 PMID: 23248274
Mediavilla-Varela et al (2013) Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Am J Transl Res 14 860 PMID: 23917542
Lee et al (2012) When cytokinin, a plant hormone, meets the adenosine A2A receptor: a novel neuroprotectant and lead for treating neurodegenerative disorders? PLoS One 7 e38865 PMID: 22719969
Kan et al (2012) Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol 86 10338 PMID: 22787201
Mills et al (2012) Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis. J Neurosci 9 193 PMID: 22883932
Teng and Mustafa (2011) A(2A) adenosine receptor-mediated increase in coronary flow in hyperlipidemic APOE-knockout mice. J Exp Pharmacol 2011 59 PMID: 21847356
Garavaglia et al (2010) Adaptation of NS cells growth and differentiation to high-throughput screening-compatible plates. BMC Neurosci 11 7 PMID: 20085655
Higley and Sabatini (2010) Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 13 958 PMID: 20601948
Alam et al (2009) A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol 2 232 PMID: 19262506
Wilson et al (2009) The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol 182 4616 PMID: 19342636
Xi et al (2009) Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 47 684 PMID: 19695259
Guerreiro et al (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 74 980 PMID: 18621927
Shen et al (2008) Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321 848 PMID: 18687967
Do you know of a great paper that uses SCH 58261 from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.